NASDAQ:ITCIIntra-Cellular Therapies Stock Price, Forecast & News

$21.59

+0.22 (+1.03 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$21.34

Now: $21.59▼

$22.26

50-Day Range

$16.45

MA: $19.78▼

$23.66

52-Week Range

$6.75

Now: $21.59▼

$43.56

Volume913,465 shs

Average Volume1.15 million shs

Market Capitalization$1.43 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.86

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Intra-Cellular Therapies has received a consensus rating of Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $37.13, Intra-Cellular Therapies has a potential upside of 72.0% from its current price of $21.59.
Amount of Analyst Coverage
Intra-Cellular Therapies has received no research coverage in the past 90 days.

2.6 Community Rank

Outperform Votes
Intra-Cellular Therapies has received 432 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Intra-Cellular Therapies has received 398 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Intra-Cellular Therapies has received 52.05% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote “Outperform” if you believe ITCI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ITCI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Intra-Cellular Therapies does not currently pay a dividend.
Dividend Growth
Intra-Cellular Therapies does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,148,037.00 in company stock.
Percentage Held by Insiders
Only 18.20% of the stock of Intra-Cellular Therapies is held by insiders.
Percentage Held by Institutions
72.25% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($3.44) to ($3.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intra-Cellular Therapies is -7.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intra-Cellular Therapies is -7.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Intra-Cellular Therapies has a P/B Ratio of 6.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.54 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ITCI

Previous Symbol

CUSIPN/A

CIK1567514

Webwww.intracellulartherapies.com

Phone646-440-9333

Debt

Debt-to-Equity Ratio0.05

Current Ratio14.83

Quick Ratio14.79

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$60,000.00

Price / Sales23,911.28

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.52 per share

Price / Book6.13

Profitability

EPS (Most Recent Fiscal Year)($2.68)

Net Income$-147,720,000.00

Net MarginsN/A

Return on Equity-57.81%

Return on Assets-48.47%

Miscellaneous

Employees73

Outstanding Shares66,451,000

Market Cap$1.43 billion

Next Earnings Date8/5/2020 (Estimated)

OptionableOptionable

Receive ITCI News and Ratings via Email

Sign-up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.

Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions

How has Intra-Cellular Therapies' stock been impacted by COVID-19 (Coronavirus)?

Intra-Cellular Therapies' stock was trading at $17.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ITCI stock has increased by 21.5% and is now trading at $21.59. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Intra-Cellular Therapies?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Intra-Cellular Therapies.

When is Intra-Cellular Therapies' next earnings date?

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Intra-Cellular Therapies.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies Inc (NASDAQ:ITCI) announced its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the Zacks' consensus estimate of ($0.93) by $0.20. The biopharmaceutical company had revenue of $1.08 million for the quarter, compared to analyst estimates of $1.75 million. View Intra-Cellular Therapies' earnings history.

What price target have analysts set for ITCI?

10 equities research analysts have issued 1 year price targets for Intra-Cellular Therapies' shares. Their forecasts range from $16.00 to $68.00. On average, they expect Intra-Cellular Therapies' share price to reach $37.13 in the next year. This suggests a possible upside of 72.0% from the stock's current price. View analysts' price targets for Intra-Cellular Therapies.

Has Intra-Cellular Therapies been receiving favorable news coverage?

News coverage about ITCI stock has been trending somewhat positive on Friday, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Intra-Cellular Therapies earned a news impact score of 0.7 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutIntra-Cellular Therapies.

Who are some of Intra-Cellular Therapies' key competitors?

Some companies that are related to Intra-Cellular Therapies include United Therapeutics (UTHR), Myokardia (MYOK), Forty Seven (FTSV), Emergent Biosolutions (EBS), Reata Pharmaceuticals (RETA), PPD (SDGR), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Evotec (EVTCY), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), GW Pharmaceuticals PLC- (GWPH), Biohaven Pharmaceutical (BHVN) and Blueprint Medicines (BPMC). View all competitors.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Amarin (AMRN), Crispr Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Gilead Sciences (GILD), AbbVie (ABBV), Clovis Oncology (CLVS), Novavax (NVAX), Myovant Sciences (MYOV), ACADIA Pharmaceuticals (ACAD) and Karyopharm Therapeutics (KPTI).

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the following people:

Dr. Sharon Mates, Co-Founder, Chairman, CEO & Pres (Age 66)
Mr. Lawrence J. Hineline CPA, Sr. VP of Fin., CFO, Treasurer and Assistant Sec. (Age 63)
Dr. Robert E. Davis, Sr. VP & Chief Scientific Officer (Age 68)
Mr. Michael I. Halstead J.D., Exec. VP, Gen. Counsel, Corp. Compliance Officer & Sec. (Age 46)
Dr. Andrew Satlin M.D., Exec. VP & Chief Medical Officer (Age 64)

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.70%), Wasatch Advisors Inc. (4.43%), State Street Corp (1.86%), Samlyn Capital LLC (1.74%), Schroder Investment Management Group (1.68%) and St. Louis Trust Co (1.33%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View institutional ownership trends for Intra-Cellular Therapies.

Which major investors are selling Intra-Cellular Therapies stock?

ITCI stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, JPMorgan Chase & Co., Voloridge Investment Management LLC, General American Investors Co. Inc., DCF Advisers LLC, CSS LLC IL, and UBS Group AG. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, and Sharon Mates. View insider buying and selling activity for Intra-Cellular Therapies.

Which major investors are buying Intra-Cellular Therapies stock?

ITCI stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Ikarian Capital LLC, Samlyn Capital LLC, St. Louis Trust Co, BlackRock Inc., Alyeska Investment Group L.P., Schroder Investment Management Group, and Invesco Ltd.. View insider buying and selling activity for Intra-Cellular Therapies.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $21.59.

How big of a company is Intra-Cellular Therapies?

Intra-Cellular Therapies has a market capitalization of $1.43 billion and generates $60,000.00 in revenue each year. The biopharmaceutical company earns $-147,720,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.

What is Intra-Cellular Therapies' official website?

The official website for Intra-Cellular Therapies is www.intracellulartherapies.com.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff